What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Mutation
Raphael Schiffmann mainly focuses on Fabry disease, Internal medicine, Enzyme replacement therapy, Endocrinology and Pathology.
His Fabry disease study combines topics in areas such as Cerebral blood flow, Vascular disease and Renal function.
His studies deal with areas such as Gastroenterology and Neuropathic pain as well as Internal medicine.
His Enzyme replacement therapy research includes themes of Surgery, Kidney disease, Urology, Nephropathy and Fabry's disease.
His research investigates the connection with Endocrinology and areas like Pathogenesis which intersect with concerns in Bioinformatics, Parkinson's disease and Proband.
He has included themes like Magnetic resonance imaging and Encephalopathy in his Pathology study.
His most cited work include:
- Enzyme replacement therapy in Fabry disease: a randomized controlled trial. (1054 citations)
- Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources (398 citations)
- Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. (350 citations)
What are the main themes of his work throughout his whole career to date?
Raphael Schiffmann spends much of his time researching Fabry disease, Internal medicine, Pathology, Enzyme replacement therapy and Endocrinology.
His Fabry disease research integrates issues from Surgery, Vascular disease and Renal function.
His biological study spans a wide range of topics, including Gastroenterology, Oncology and Cardiology.
His work focuses on many connections between Pathology and other disciplines, such as White matter, that overlap with his field of interest in Leukoencephalopathy.
His Enzyme replacement therapy research is multidisciplinary, relying on both Nephropathy, Alpha-galactosidase, Kidney and Urology.
His research investigates the link between Leukodystrophy and topics such as Genetics that cross with problems in Molecular biology.
He most often published in these fields:
- Fabry disease (46.75%)
- Internal medicine (30.18%)
- Pathology (24.56%)
What were the highlights of his more recent work (between 2015-2021)?
- Fabry disease (46.75%)
- Internal medicine (30.18%)
- Migalastat (7.99%)
In recent papers he was focusing on the following fields of study:
Fabry disease, Internal medicine, Migalastat, Enzyme replacement therapy and Pharmacology are his primary areas of study.
His study on Globotriaosylceramide is often connected to In patient as part of broader study in Fabry disease.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology and Cardiology.
The concepts of his Endocrinology study are interwoven with issues in Priapism and Pathogenesis.
Pathology covers he research in Migalastat.
As part of one scientific family, Raphael Schiffmann deals mainly with the area of Enzyme replacement therapy, narrowing it down to issues related to the Alpha-galactosidase, and often Fabry's disease and Nephropathy.
Between 2015 and 2021, his most popular works were:
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat (211 citations)
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat (211 citations)
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. (93 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Mutation
Raphael Schiffmann mostly deals with Fabry disease, Enzyme replacement therapy, Internal medicine, Pharmacology and Alpha-galactosidase.
His research in Fabry disease is mostly concerned with Globotriaosylceramide.
His work deals with themes such as Adverse effect, Kidney, Renal function and Urology, which intersect with Enzyme replacement therapy.
His Internal medicine research incorporates themes from Endocrinology and Cardiology.
In Pharmacology, Raphael Schiffmann works on issues like Migalastat, which are connected to Nephropathy, Fabry's disease, Pharmacological chaperone, Migalastat Hydrochloride and Oncology.
His research in Alpha-galactosidase intersects with topics in Receptor, Biochemistry and Mannose.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
